Cover Image
市場調查報告書

慢性腎臟病 (CKD) 的主要19個國家市場預測

Chronic Kidney Disease (CKD) Forecast in 19 Major Markets 2016-2026

出版商 Black Swan Analysis 商品編碼 356340
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
慢性腎臟病 (CKD) 的主要19個國家市場預測 Chronic Kidney Disease (CKD) Forecast in 19 Major Markets 2016-2026
出版日期: 2016年04月18日 內容資訊: 英文 74 Pages
簡介

本報告提供全球主要19個國家市場上慢性腎臟病之罹患情形調查,提供您得病數的變化與預測,性別·病情等各種類別的明細,並彙整疾病概要,危險因素,疾病診斷預後,主要的症狀和併發症等資料。

調查對象國家

  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 巴西
  • 日本
  • 印度
  • 土耳其
  • 墨西哥
  • 澳洲
  • 加拿大
  • 挪威
  • 愛爾蘭
  • 荷蘭
  • 波蘭
  • 韓國
  • 中國

目錄

  • 簡介
  • 病因
  • 危險因素和預防
  • 疾病診斷
  • 地區/各民族的差異
  • 疾病預後和臨床過程
  • 疾病相關的主要併發症/特徵
  • 患者數定量化的手法
  • CKD的患病人數
  • CKD患者的特徵
    • 疾病階段
    • ESRD治療
    • CKD患者的相關症狀
    • ESRD患者的相關症狀
  • 簡稱
  • 相關出版物
  • 線上資料庫
  • 參考文獻
  • 附錄
目錄
Product Code: CHKD0010416

image1

Chronic kidney disease (CKD), also known as chronic renal disease, is characterised by progressive loss of kidney function over time. CKD is defined as persisting kidney damage or a glomerular filtration rate (GFR) of <60 mL/min/1.73 m2 for ≥ 3 months. This damage refers to any renal pathology that has the potential to cause a reduction in renal functional capacity, such as GFR.

This report provides the current prevalent population for CKD across 19 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Turkey, Mexico, Australia, Canada, Norway, Ireland, Netherlands, Poland, South Korea and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of CKD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for CKD include:

  • Hypertension
  • Diabetes
  • Chronic heart failure
  • Anaemia
  • Hyperphosphatemia
  • Increased risk of infection
  • End stage renal disease
  • Acute kidney injury

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global CKD's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of CKD and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on CKD's prevalent population.
  • Identify sub-populations within CKD which require treatment.
  • Gain an understanding of the specific markets that have the largest number of CKD patients.

Coverage

AU, BR, CA, CN, FR, DE, IN, IE, IT, JP, MX, NL, NO, PL, KR, ES, TR, UK, US

image2

Table of Contents

List of Tables and Figures

Introduction

Cause of the Disease

Risk Factors & Prevention

Diagnosis of the Disease

Variation by Geography/Ethnicity

Disease Prognosis & Clinical Course

Key Co-morbid Conditions/Features Associated with the Disease

Methodology for Quantification of Patient Numbers

  • Additional data available on request

Top-Line Prevalence for Chronic Kidney Disease

Features of Chronic Kidney Disease Patients

  • CKD by Stage of Disease
  • ESRD Therapy
  • Associated Conditions of CKD Patients
  • Associated Conditions of ESRD Patients

Abbreviations used in the Report

Other Black Swan Analysis Publications

Black Swan Analysis Online Patient-Based Databases

Patient-Based Offering

Online Pricing Data and Platforms

References

Appendix

List of Tables

  • National Kidney Foundation's CKD KDOQI Clinical Practice Guidelines for CKD
  • Prevalence of CKD, total (000s)
  • Prevalence of CKD, males (000s)
  • Prevalence of CKD, females (000s)
  • Stage of CKD patients, total (000s)
  • Renal replacement therapy in Stage V (ESRD) CKD patients, total (000s)
  • Prevalence of diabetes in CKD, total (000s)
  • Prevalence of elevated CRP in CKD, total (000s)
  • Prevalence of myocardial infarction in CKD, total (000s)
  • Prevalence of diabetes in ESRD patients, total (000s)
  • Prevalence of hypertension in ESRD patients, total (000s)
  • Prevalence of glomerulonephritis in ESRD patients, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of CKD by 5-yr age cohort, males (000s)
  • USA Prevalence of CKD by 5-yr age cohort, females (000s)
  • France Prevalence of CKD by 5-yr age cohort, males (000s)
  • France Prevalence of CKD by 5-yr age cohort, females (000s)
  • Germany Prevalence of CKD by 5-yr age cohort, males (000s)
  • Germany Prevalence of CKD by 5-yr age cohort, females (000s)
  • Italy Prevalence of CKD by 5-yr age cohort, males (000s)
  • Italy Prevalence of CKD by 5-yr age cohort, females (000s)
  • Spain Prevalence of CKD by 5-yr age cohort, males (000s)
  • Spain Prevalence of CKD by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of CKD by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of CKD by 5-yr age cohort, females (000s)
  • Brazil Prevalence of CKD by 5-yr age cohort, males (000s)
  • Brazil Prevalence of CKD by 5-yr age cohort, females (000s)
  • Japan Prevalence of CKD by 5-yr age cohort, males (000s)
  • Japan Prevalence of CKD by 5-yr age cohort, females (000s)
  • India Prevalence of CKD by 5-yr age cohort, males (000s)
  • India Prevalence of CKD by 5-yr age cohort, females (000s)
  • Turkey Prevalence of CKD by 5-yr age cohort, males (000s)
  • Turkey Prevalence of CKD by 5-yr age cohort, females (000s)
  • Mexico Prevalence of CKD by 5-yr age cohort, males (000s)
  • Mexico Prevalence of CKD by 5-yr age cohort, females (000s)
  • Australia Prevalence of CKD by 5-yr age cohort, males (000s)
  • Australia Prevalence of CKD by 5-yr age cohort, females (000s)
  • Canada Prevalence of CKD by 5-yr age cohort, males (000s)
  • Canada Prevalence of CKD by 5-yr age cohort, females (000s)
  • Norway Prevalence of CKD by 5-yr age cohort, males (000s)
  • Norway Prevalence of CKD by 5-yr age cohort, females (000s)
  • Ireland Prevalence of CKD by 5-yr age cohort, males (000s)
  • Ireland Prevalence of CKD by 5-yr age cohort, females (000s)
  • Netherlands Prevalence of CKD by 5-yr age cohort, males (000s)
  • Netherlands Prevalence of CKD by 5-yr age cohort, females (000s)
  • Poland Prevalence of CKD by 5-yr age cohort, males (000s)
  • Poland Prevalence of CKD by 5-yr age cohort, females (000s)
  • South Korea Prevalence of CKD by 5-yr age cohort, males (000s)
  • South Korea Prevalence of CKD by 5-yr age cohort, females (000s)
  • China Prevalence of CKD by 5-yr age cohort, males (000s)
  • China Prevalence of CKD by 5-yr age cohort, females (000s)
Back to Top